EN
/
JP
News
About Us
About Us
Philosophy/Policy
Board of Directors
History
Company Information
Corporate Governance
Partner
Close
Business Strategy
Business Strategy
Business Model
Life Cycle Management Strategy
Close
Technology
Technology
SLC Transporters
LAT1 Inhibitors
Close
Pipeline
Pipeline
Development Status
Biliary Tract Cancer
Multiple Sclerosis
Other Pipelines
Close
Clinical Trials
Clinical Trials
Biliary Tract Cancer Phase III
JPH034 Phase 1
Close
IR
IR
IR News
Top Message
Disclosure Policy
Financial Highlights
IR Calendar
IR Library
Financial Results
Presentation Materials
IR Materials
Stock Information
Stock Overview
General Meeting of Shareholders
Disclaimer
Close
Contact
EN
/
JP
Close
Top
＞
News Lists
News Lists
All
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2024.06.03
Conclusion of License Agreement with Georgetown University
2024.05.16
Corporate Website Renewal Announcement
2024.01.22
J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024)
2024.01.12
J-Pharma Presenting at the J.P. Morgan Healthcare Conference 2024 for the Fourth Consecutive Year
2023.12.13
Announcement of presentation at the J.P. Morgan Healthcare Conference 2024
2023.10.05
J-Pharma Receives Award from the National Multiple Sclerosis Society to Develop JPH034 as a Potential Treatment for Progressive Multiple Sclerosis
2023.10.05
Financing total 2.4 billion yen completed through a third-party allotment of new shares (Round E)
2023.10.02
Notice of Transition to Company with Audit and Supervisory Committee and New Board of Directors Appointments
2023.06.28
Notice of Board of Directors Appointments
2023.06.26
Haruki Kusaka, Director of Clinical Development Dept. receives Outstanding Leadership Award at HEALTH 2.0 Conference (Dubai, UAE)
1
2
3
4
5
6
7
8
